Annovis Bio
ANVS
31 hedge funds and large institutions have $5.67M invested in Annovis Bio in 2024 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 8 increasing their positions, 8 reducing their positions, and 6 closing their positions.
0% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 6
0% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 8
2.62% less ownership
Funds ownership: 11.43% → 8.81% (-2.6%)
3% less funds holding
Funds holding: 32 → 31 (-1)
43% less call options, than puts
Call options by funds: $8.64M | Put options by funds: $15.2M
61% less capital invested
Capital invested by funds: $14.4M → $5.67M (-$8.74M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$161K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$100K |
| 3 |
Jane Street
New York
|
+$82K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$44.1K |
| 5 |
Belvedere Trading
Chicago,
Illinois
|
+$38.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$1.22M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$588K |
| 3 |
RAM
Redmond Asset Management
Henrico,
Virginia
|
-$430K |
| 4 |
Cetera Investment Advisers
Schaumburg,
Illinois
|
-$133K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$93.2K |
ANVS Hedge Fund Activity: Q2 2024 in Review
31 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in Annovis Bio (ANVS) for Q2 2024, worth a combined $5.67M — down 61% from $14.4M a quarter earlier.
Fund positioning in ANVS was balanced in Q2 2024: 6 funds opened new positions, 6 closed out, 8 added to existing stakes and 8 trimmed.
The largest buyer was XTX Topco, opening a new position worth an estimated $161K. The largest seller was Adage Capital Partners, cutting an estimated $1.22M.
- 31 institutional investors held Annovis Bio (ANVS) as of Q2 2024, down from 32 in Q1 2024.
- Funds reported $5.67M of Annovis Bio stock for Q2 2024, down 61% quarter-over-quarter.
- 6 funds opened new Annovis Bio positions in Q2 2024 and 6 closed out, a net change of 0 holders.
- The largest Annovis Bio buyer in Q2 2024 was XTX Topco, an estimated $161K added.
- The largest Annovis Bio seller in Q2 2024 was Adage Capital Partners, an estimated $1.22M sold.
Based on aggregated 13F filings for Q2 2024.